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Anthelmintic resistance in parasites of horses was first
reported approximately five decades ago when various
researchers noted that phenothiazine treatment failed to
reduce strongylid egg counts [1-3]. Anthelmintic resis-
tance in cyathostomin (small strongyle) nematodes has
since expanded to encompass nearly universal insuscep-
tibility to benzimidazoles [4,5], resistance to pyrantel
salts by nearly 50% of populations in the U.S. [4-6], and
occasional resistance to piperazine [7]. Lyons et al. [8]
recently reported shortened egg reappearance periods and
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Abstract
Since 2002, macrocyclic lactone resistance has been reported in populations of Parascaris equorum
from several countries. It is apparent that macrocyclic lactone resistance developed in response to
exclusive and/or excessively frequent use of ivermectin or moxidectin in foals during the first year of
life. The development of anthelmintic resistance was virtually inevitable, given certain biological
features of Parascaris and unique pharmacologic characteristics of the macrocyclic lactones.
Practitioners can utilize the Fecal Egg Count Reduction Test to detect anthelmintic resistance in
Parascaris, and the same technique can be applied regularly to confirm the continued efficacy of those
drugs currently in use. In the face of macrocyclic lactone resistance, piperazine or anthelmintics of the
benzimidazole or pyrimidine classes can be used to control ascarid infections, but Parascaris
populations that are concurrently resistant to macrocyclic lactones and pyrimidine drugs have been
reported recently from Texas and Kentucky. Compared to traditional practices, future recommen-
dations for ascarid control should feature: 1) use of only those anthelmintics known to be effective
against indigenous populations, 2) initiation of anthelmintic treatment no earlier than 60 days of age,
and 3) repetition of treatments at the longest intervals which prevent serious environmental contami-
nation with Parascaris eggs. In the interest of decreasing selection pressure for anthelmintic resistance,
horse owners and veterinarians must become more tolerant of the passage of modest numbers of
ascarid eggs by some foals. Anthelmintic resistance is only one of several potential responses to
genetic selection.Although still only theoretical, changes in the immunogenicity of ascarid isolates or
reduction of their prepatent or egg reappearance periods could pose far greater challenges to
effective control than resistance to a single class of anthelmintics.
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survival of fourth-stage larval cyathostomins following
treatment with macrocyclic lactone anthelmintics. These
phenomena are considered to be companions and
precursors of clinical anthelmintic resistance.
Yet, most concerns that parasitologists and equine
practitioners harbored about anthelmintic-resistant
cyathostomins were mitigated by the fact that small
strongyles are generally not serious pathogens in well-
managed horses. Concern was amplified into alarm,
however, by the first published reports of anthelmintic
resistance in Parascaris equorum [9,10]. P. equorum is the
most pathogenic parasite of juvenile equids, and can
cause poor growth, ill-thrift, weight loss, colic, and death
subsequent to intestinal impaction or perforation.
Although the parasitology community was taken aback by
the development of macrocyclic lactone (ML) resistance
in a non-strongylid nematode, an honest assessment of
historical management practices for equine ascarids, with
due application of resistance selection theory, should
have predicted this circumstance. In retrospect, perhaps
the most surprising element about the development of
macrocyclic lactone resistance in equine ascarids is that it
did not arise until nearly 20 years after the first approval
of ivermectin for horses.
Horse owners and equine practitioners are now aware of
anthelmintic-resistance in ascarids, and have numerous
practical questions regarding its detection, management,
and prevention. The objectives of this paper are to review
the current status of anthelmintic resistance in popula-
tions of P. equorum, to discuss the biological and manage-
ment factors which promoted its development, and to
offer practical methods of detection, chemical control,
and prevention for breeding stables.
Life cycle
P. equorum (ascarid; roundworm) is a common nematode
parasite which occurs in the small intestine of immature
horses world-wide. Adult female ascarids lay eggs in the
small intestine, and these eggs pass into the environment
within the feces of the host. The infective stage is a
larvated egg (containing a second stage larva [L3]);
development requires approximately 10 days at tempera-
tures of 25°C to 35°C [11]. Larvated eggs survive in the
environment for up to five or 10 years, and infection is
acquired through inadvertent ingestion of eggs. Larvae
emerge from eggs within the alimentary tract of a horse,
and migrate through the liver and lungs before returning
to the small intestine approximately one month later as
fourth stage larvae (L4). Ascarids mature progressively in
the small intestine and achieve patency about 75 to
80 days after infection [11].
P. equorum is one of the rare nematodes which induces
absolute acquired immunity. Most horses become immune
during the first year of life, so patent ascarid infections are
rarely diagnosed in horses over two years of age.
Anthelmintic resistance
Failures of macrocyclic lactone treatment to decrease
Parascaris fecal egg counts were first reported in the
Netherlands [9] and Canada [10]. Subsequently, macro-
cyclic lactone-resistant (ML-R) populations of P. equorum
have been detected in numerous countries, including the
United States [12,13], Denmark [14], Germany [15],
Brazil [16], and Italy [17]. A comprehensive survey of the
distribution of ML-R Parascaris populations has not been
conducted, but anecdotal reports abound in North
America.
The initial clinical evidence of macrocyclic lactone
resistance (ML-R) consisted of failures of ivermectin
(IVM) or moxidectin (MOX) to decrease ascarid egg
counts after treatment. To characterize this phenomenon
more thoroughly, an efficacy study was conducted in
2005 with 11 foals that had been raised helminth-free.
These foals were inoculated orally at 6 weeks to
3 months of age with ~500 larvated eggs of a Canadian
isolate of P. equorum that was purportedly resistant to
macrocyclic lactone anthelmintics [18]. Six foals were
treated orally with ivermectin paste (200 μg/kg), and the
remaining five served as untreated controls. Ivermectin
treatment did not result in significant Fecal Egg Count
Reduction (FECR), and worm numbers at necropsy were
decreased by only 22%. This study unequivocally
confirmed ivermectin resistance in P. equorum, and a
subsequent study wherein alternating treatments of
ivermectin and moxidectin failed to reduce egg counts
demonstrated that such resistance involved the entire
macrocyclic lactone class [19].
Inherent factors contributing to resistance
All currently marketed equine anthelmintics are con-
sidered to be “broad spectrum”, meaning they have good
efficacy (>90%) against four groups of target parasites:
large strongyles, cyathostomins, ascarids, and pinworms.
Broad spectrum anthelmintics are not uniformly effective
against all parasitic targets; invariably, one parasite always
requires a higher dosage than the others to achieve
efficacy [20]. These hardest-to-kill species are known as
dose-limiting parasites (DLPs), and P. equorum is the DLP
for most equine anthelmintics.
The clearest example of Parascaris as a DLP is seen with
fenbendazole (FBZ). In horses, the 5 mg/kg dosage of FBZ
is effective against large strongyles, susceptible cyatho-
stomins, and pinworms, but the recommended dosage for
removal of Parascaris is 10 mg FBZ/kg body weight.
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Because the magnitude of difference between an effective
dosage and the label dosage is much less for DLPs than
for other intended targets, dose-limiting parasites have a
lower threshold for the development of resistance.
Pharmacologic factors selecting for resistance
Macrocyclic lactones are the most persistent anthel-
mintics used in horses, and effective drug levels may
persist in the plasma for days to weeks after a single
treatment. Drug concentrations inevitably decline,
however, and parasites that are newly acquired during this
phase may be exposed to subtherapeutic concentrations
as a consequence. Low drug concentrations during the
decay phase of persistent products can select for anthel-
mintic resistance (so-called “tail selection”) [21].
In contrast, anthelmintics of the pyrimidine and
benzimidazole classes are non-persistent. Resistance of
P. equorum to pyrantel pamoate has been reported
recently in herds from Texas and Kentucky [12,13].
Pyrantel pamoate resistance was possibly pre-selected by
daily use of pyrantel tartrate in some herds for prevention
of ascarid and strongyle infections. Pyrantel-resistant
ascarids have not been reported outside of North
America, which is the exclusive marketing range of
pyrantel tartrate for prophylactic use in horses [5]. Ascarid
resistance to benzimidazoles has not been reported in
North America, perhaps because use of this class has been
limited to non-persistent, therapeutic applications.
Control practices which select for resistance
Anthelmintics are used excessively by many breeding
farms, where it is a common practice to administer iver-
mectin for treatment of suspected Strongyloides infection
when foals are less than one month of age. Thereafter,
frequent anthelmintic rotation is implemented, and
juvenile horses are often dewormed at monthly intervals
until their first birthday. Many farms use macrocyclic
lactones at least bimonthly in juvenile horses [12].
Because macrocyclic lactones are larvicidal against
Parascaris, the refugia within a host is minimized each
time an infected foal is dosed. This happens routinely
whenever the interval between treatments is shorter than
the prepatent period for Parascaris (i.e., 75-80 days). In
addition, susceptible genotypes in the local population
are denied an opportunity to reproduce whenever
macrocyclic lactone treatments are repeated at intervals
which are less than the prepatent period or egg reappear-
ance period, thus minimizing refugia in the environment.
Typical parasite control practices for juvenile horses at
many breeding operations essentially constitute exclusive
and/or excessively frequent use of a single drug class, and
thus select intensively for anthelmintic resistance [4].
Transmission among facilities
It is likely that macrocyclic lactone resistance arose
independently at multiple locations, and may do so again
at any facility where traditional control practices are
followed. As the prevalence of macrocyclic lactone-
resistant ascarids increases, farms are at ever greater risk of
inadvertently importing a resistant isolate.
The major potential source is foals which harbor
immature infections. Fecal examination of such animals
would be fruitless because their worm burdens are not yet
capable of sexual reproduction. This particular route of
dissemination is a great threat to the Thoroughbred
industry, which requires that offspring must be sired by
natural service in order to be registered. This requirement
results in significant traffic of mares, with foals-at-side, to
breeding facilities for natural service by a stallion. If a foal
acquires a macrocyclic-lactone resistant ascarid infection
at the breeding farm, it will transport it back home, and
only time will reveal its presence. Treatment of returning
foals with ivermectin or moxidectin is ineffective because
the target infection is ML-R. Carefully timed
administration of non-ML anthelmintics could reduce the
number of resulting adult worms, but probably would
not eliminate them totally.
Detection of resistant isolates
Fecal flotation is a simple, inexpensive, and widely
available procedure for detecting patent Parascaris
infections in horses. Quantitative procedures (e.g.,
McMaster, Modified Stoll, Sucrose Centrifugation) provide
valuable information regarding the magnitude of
environmental contamination by individual animals.
However, a correlation between egg counts (eggs per gram;
EPG) and worm burdens has not been demonstrated for P.
equorum, so one may not assume that horses with high egg
counts are harboring large numbers of mature ascarids.
The Fecal Egg Count Reduction Test (FECRT) is the
standard method for detecting anthelmintic resistance in
cyathostomin nematodes of horses, but this procedure
has not been validated for Parascaris. Nevertheless, FECRT
is the only currently available test for quantifying
anthelmintic removal of reproducing, adult, female
Parascaris from an individual horse.
Parascaris FECRT can only be performed with horses that
have positive egg counts, and some minimum quanti-
tative standard (e.g., ≥200 EPG) should be established for
inclusion in FECR calculations. Enrollment of large
numbers of horses in an efficacy evaluation will provide a
more accurate representation of the susceptibility status
of the resident ascarid population. Following deter-
mination of pretreatment fecal egg counts, each candidate
is treated according to label directions with the
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anthelmintic to be screened. Between 14-21 days after
treatment, fecal samples are collected from the same
individuals that were screened pretreatment, and fecal egg
counts are repeated. Fecal Egg Count Reduction (FECR) is
a measure of anthelmintic efficacy, expressed in percen-
tages, and is calculated by the formula:
FECR = (Meanpretreatment - meanpost-treatment) / Meanpretreatment × 100
The magnitude of egg count reduction which comprises
acceptable efficacy is generally accepted as >90% or >95%
FECR. These ranges constitute rough guidelines only, but
will have to serve until FECRT has been validated for
Parascaris.
Anthelmintic resistance appears to be a permanent
genetic feature of a parasite population, and reversion to
susceptibility may never occur. Accordingly, if the resident
ascarid population is resistant to a particular drug class,
products from that chemical group should never again be
used alone for ascarid control on those premises.
However, drugs to which ascarids are resistant may retain
substantial efficacy against other important equine
parasites, such as large strongyles or cyathostomins. Any
drug classes that are known to be effective against the
indigenous ascarid isolate should be evaluated annually
for continued efficacy.
Control recommendations
Ideally, a decision to administer anthelmintics for
removal of P. equorum infections would be based on a
positive diagnostic result (e.g., fecal examination) for
each animal to be treated. However, confirmation of
patency also indicates that the environment is being
contaminated with highly persistent ascarid eggs, which
confounds the universal objective of parasite control.
Ultimately, compromise is unavoidable, and some level
of contamination must be accepted because suppressive
programs select too intensively for the development of
resistance. And, whenever treatment is indicated, it is
desirable to use only anthelmintics with known efficacy
against indigenous parasite populations.
The specter of Strongyloides westeri infection is not
sufficient justification for deworming foals with MLs
during the first month of life. Strongyloides is relatively
uncommon and only occasionally pathogenic. Initial
treatment of foals for Parascaris infection should not
begin earlier than 60 to 70 days of age, and treatments
thereafter should be repeated at the longest intervals
which minimize environmental contamination with
ascarid eggs.
One important feature of ascarid biology that should be
considered in scheduling Parascaris treatments is that
anthelmintic efficacy apparently increases as the target
population ages. For example, oxibendazole (10 mg/kg)
was 94% [13] to 100% [22] effective against patent (i.e.,
mature) ascarid infections when measured by FECRT.
However, the same dosage removed only 44.5% of
immature ascarids when administered at 28 days post-
infection [23]. So, it is logical that anthelmintic treat-
ments would be more effective against ascarids if
administered just prior to patency, i.e., at 70 to 75 days
post-infection. This knowledge has limited practical
application, however, because natural infections “trickle”
into the host, with multiple exposures occurring continu-
ously on a daily basis. A foal with a negative fecal result
could harbor ascarid populations ranging in age from 1 to
75 days, and anthelmintics directed against such a mixed
population would likely remove the older ascarids but
demonstrate little efficacy against juvenile worms.
Traditional recommendations for ascarid control are to
treat foals at bimonthly intervals (i.e., q ~60 days), but
this schedule may be insufficiently frequent to minimize
the passage of eggs in the feces of some foals. However,
deworming more frequently, especially with macrocyclic
lactone anthelmintics, minimizes refugia and selects for
resistance. It may be preferable to tolerate some level of
egg contamination, because a survey in the Netherlands
found little ML resistance on farms where foals were de-
wormed less frequently than at bimonthly intervals [24].
If anthelmintic resistance is not an issue, acceptable
efficacy can usually be achieved with any of the products
listed in Table 1.
If ML-R ascarids are present on a farm, benzimidazole or
pyrimidine formulations can be administered easily and
usually provide good efficacy. Rotation between effective
drug classes is recommended [25-26]. Recently, ML-R
Parascaris populations that are simultaneously resistant to
pyrantel pamoate have been reported from Texas [12] and
Kentucky [13]. For these populations, the only remaining,
effective drugs are piperazine, fenbendazole, or oxibenda-
zole. Due to the possibility of multiple drug resistance,
the continuing efficacy of all drug classes used against
Parascaris should be confirmed annually on each farm.
Preventing the introduction of a ML-R strain to a farm is
particularly difficult to manage, because the infection
cannot be detected and efficacy cannot be verified.
Furthermore, non-ML anthelmintics have no efficacy
against migrating stages during the first month post-
treatment, and only partial efficacy thereafter until the
population becomes fully mature.
A regimen of fenbendazole, 10 mg/kg daily for five
consecutive days represents one possible tool for
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preventing the inadvertent introduction of a resistant
isolate. A previous study demonstrated that this regimen
of fenbendazole was 99.7% effective when administered
between 11-15 days post-infection [27]. Although
multiple-day fenbendazole is not specifically approved
for removal of immature Parascaris infections, it is labeled
for larvicidal therapy of migrating large strongyles and
encysted cyathostomins. The suggested prophylactic uses
of this regimen include treatment of foals when they
return with their dams from a breeding facility, or
treatment of any juveniles upon first introduction to a
new facility.
Possible biological changes
Anthelmintic resistance is only one manifestation of
genetic change in a parasite population in response to
various selection pressures. Other biological adaptations
are certainly feasible, and some could even impact
practical control more deleteriously than drug resistance.
For instance, acquired immunity is the ultimate ally in
controlling equine ascarids, but if P. equorum isolates with
low immunogenicity were to evolve, the challenges of
ascarid control could extend to horses of all ages, rather
than just juveniles. Variations from the typical host age
spectrum have been reported with Oxyuris equi, and
altered immunity is one feasible explanation [28].
It is also possible that the prepatent period or egg re-
appearance period of Parascaris could become abbreviated
as a response to frequent anthelmintic treatment. This
phenomenon has not yet been investigated in ascarids,
but reduction of the egg reappearance period of
cyathostomins has been documented as a consequence of
anthelmintic selection pressure [8,15,29-32].
The present and emerging threats associated with anthel-
mintic treatment lend particular urgency to the develop-
ment of sustainable approaches to parasite management
which are not exclusively dependent on chemical control.
Conclusions
The development of anthelmintic resistance in some
populations of P. equorum means that casual selection of
dewormers must be discontinued, and that treatments
can no longer be administered at frequent intervals. In the
future, the resistance status of each drug class should be
evaluated against local isolates, and efficacy should be re-
confirmed at regular intervals. The Fecal Egg Count
Reduction Test is a simple procedure which can be
adapted for this purpose. Although fecal monitoring will
increase the costs of administering control programs, the
alternative, i.e., expanding resistance, is unacceptable.
Future management of the entire spectrum of equine
parasites lies in the development of sustainable approaches
which do not rely solely on anthelmintic treatment.
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